| Literature DB >> 33153883 |
Amelia Van Pelt1, Henry A Glick2, Wei Yang3, David Rubin4, Michael Feldman5, Stephen E Kimmel6.
Abstract
PURPOSE: The optimal approach to identify SARS-CoV-2 infection among college students returning to campus is unknown. Recommendations vary from no testing to two tests per student. This research determined the strategy that optimizes the number of true positives and negatives detected and reverse transcription polymerase chain reaction (RT-PCR) tests needed.Entities:
Keywords: COVID-19; College students; Decision analysis; Testing
Year: 2020 PMID: 33153883 PMCID: PMC7606071 DOI: 10.1016/j.jadohealth.2020.09.038
Source DB: PubMed Journal: J Adolesc Health ISSN: 1054-139X Impact factor: 5.012
Parameters for decision tree analysis
| Variable | Estimate (range) | Source | Distribution |
|---|---|---|---|
| COVID-19 prevalence | .0045 (0–.1000) | [ | Beta |
| Proportion of symptomatic cases | .5679 (.2000–.8000) | [ | Beta |
| Proportion of symptomatic without COVID-19 | .0957 (.0500–.2000) | [ | Beta |
| Proportion of symptomatic cases in pos-tincubation period | .7143 | ||
| RT-PCR sensitivity | |||
| Incubation period (Days 1–4) | .0850 (±30%) | [ | Beta |
| Post-incubation period (Days 5–14) | .7173 (±30%) | [ | Beta |
| RT-PCR specificity | 1.0000 (.9897–1.0000) | [ | Beta |
RT-PCR = reverse transcription polymerase chain reaction.
Distribution used in second-order Monte Carlo analysis.
Based on a median 5-day incubation period and a post-incubation period of 10 days.
Number of true positives, true negatives, and number of RT-PCR per student for each strategy and estimates for a student population of 20,000
| Strategy | Mean | 95% CI | Percentage detected | Total students |
|---|---|---|---|---|
| True positives | (Out of .004473) | |||
| Symptom-based screening only | .0018 | .0016–.0020 | 40.56 | 36 |
| Symptom-based RT-PCR testing | .0013 | .0012–.0014 | 29.09 | 26 |
| Universal, Single RT-PCR testing | .0024 | .0023–.0025 | 53.66 | 48 |
| Repeat RT-PCR testing based on symptoms | .0032 | .0031–.0034 | 72.54 | 65 |
| Universal, Repeat RT-PCR testing | .0039 | .0037–.0040 | 86.90 | 78 |
| True negatives | (Out of .995527) | Percentage mistaken diagnosis of well students | (out of 19,911) | |
| Symptom-based screening only | .9002 | .8899–.9101 | 9.56 | 18,005 |
| Symptom-based RT-PCR testing | .9955 | .9945–.9955 | 0 | 19,911 |
| Universal, Single RT-PCR testing | .9955 | .9850–.9935 | 0 | 19,911 |
| Repeat RT-PCR testing based on symptoms | .9955 | .9842–.9955 | 0 | 19,911 |
| Universal, repeat RT-PCR testing | .9955 | .9747–.9955 | 0 | 19,911 |
| Number of RT-PCR tests/student | Total tests | |||
| Symptom-based screening only | .0000 | .0000–.0000 | 0 | -- |
| Symptom-based RT-PCR testing | .0971 | .0872–.1074 | 1,942 | -- |
| Universal, Single RT-PCR testing | 1.0000 | 1.0000–1.0000 | 20,000 | -- |
| Repeat RT-PCR testing based on symptoms | 1.0965 | 1.0864–1.1068 | 21,930 | -- |
| Universal, repeat RT-PCR testing | 1.9976 | 1.9871–1.9977 | 39,952 | -- |
CI = confidence interval; RT-PCR = reverse transcription polymerase chain reaction.
Rounded to nearest integer.
Number per 20,000 students.
Figure 1Ranges of acceptable tests per true positive (TTP) identified from cost-effectiveness for five RT-PCR based strategies. Columns represent values of TTP for which the different screening strategies are preferred for probabilities of COVID-19 of .4473%, 1%, 5%, and 10%. Red narrower cross hatch represents the TTP for which (Strategy 2) symptom-based testing or (Strategy 1) symptom-based screening is preferred; green narrower diagonal represents the TTP for which (Strategy 1) symptom-based screening or (Strategy 4) retesting students with negative tests and symptoms is preferred; blue wider cross hatch represents (Strategy 4) retesting students with negative tests and symptoms is preferred; and magenta wider diagonal represents (Strategy 5) retesting all students with negative tests is preferred. Strategy 3 is never preferred because of weak dominance. RT-PCR, reverse transcription polymerase chain reaction.
Figure 2Sensitivity analysis for primary outcomes with varying probabilities of COVID-19. Results among a population of 20,000 students. (A) Number of true positives; (B) Number of true negatives; (C) Number of RT-PCR tests. For A and C, green line represents Strategy 1: symptom-based screening only (NoS). Red line represents Strategy 2: symptom-based RT-PCR testing (Symp). Purple line represents Strategy 3: universal, single RT-PCR testing (All). Blue line represents Strategy 4: repeat RT-PCR based on symptoms (Re1). Pink line is Strategy 5: universal repeat RT-PCR testing (Re2). For B, green line represents Strategy 1, whereas mixed line represents Strategies 2–5. RT-PCR, reverse transcription polymerase chain reaction.
Figure 3Sensitivity analysis for primary outcomes with varying RT-PCR sensitivity and specificity and for proportion of (eventually) symptomatic COVID-19 cases. (A) Number of true positives with varying sensitivity; (B) Number of true negatives with varying specificity; (C) Number of true positives with varying proportions of eventually symptomatic disease. Green line represents Strategy 1: symptom-based screening only. Red line represents Strategy 2: symptom-based RT-PCR testing. Purple line represents Strategy 3: universal, single RT-PCR testing. Blue line represents Strategy 4: repeat RT-PCR based on symptoms. Pink line represents Strategy 5: universal repeat RT-PCR testing. RT-PCR, reverse transcription polymerase chain reaction.